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Background-—Blood outgrowth endothelial cells (BOECs) mediate therapeutic neovascularization in experimental models, but
outgrowth characteristics and functionality of BOECs from patients with ischemic cardiomyopathy (ICMP) are unknown. We
compared outgrowth efficiency and in vitro and in vivo functionality of BOECs derived from ICMP with BOECs from age-matched
(ACON) and healthy young (CON) controls.
Methods and Results-—We isolated 3.60.6 BOEC colonies/1009106 mononuclear cells (MNCs) from 60-mL blood samples of
ICMP patients (n=45; age: 661 years; LVEF: 312%) versus 3.50.9 colonies/1009106 MNCs in ACON (n=32; age:
601 years) and 2.60.4 colonies/1009106 MNCs in CON (n=55; age: 341 years), P=0.29. Endothelial lineage (VEGFR2+/
CD31+/CD146+) and progenitor (CD34+/CD133) marker expression was comparable in ICMP and CON. Growth kinetics were
similar between groups (P=0.38) and not affected by left ventricular systolic dysfunction, maladaptive remodeling, or presence of
cardiovascular risk factors in ICMP patients. In vitro neovascularization potential, assessed by network remodeling on Matrigel and
three-dimensional spheroid sprouting, did not differ in ICMP from (A)CON. Secretome analysis showed a marked proangiogenic
profile, with highest release of angiopoietin-2 (1.40.39105 pg/106 ICMP-BOECs) and placental growth factor
(5.81.59103 pg/106 ICMP BOECs), independent of age or ischemic disease. Senescence-associated b-galactosidase staining
showed comparable senescence in BOECs from ICMP (5.82.1%; n=17), ACON (3.91.1%; n=7), and CON (9.02.8%; n=13),
P=0.19. High-resolution microcomputed tomography analysis in the ischemic hindlimb of nude mice confirmed increased
arteriogenesis in the thigh region after intramuscular injections of BOECs from ICMP (P=0.025; n=8) and CON (P=0.048; n=5) over
vehicle control (n=8), both to a similar extent (P=0.831).
Conclusions-—BOECs can be successfully culture-expanded from patients with ICMP. In contrast to impaired functionality of ICMP-
derived bone marrow MNCs, BOECs retain a robust proangiogenic profile, both in vitro and in vivo, with therapeutic potential for
targeting ischemic disease. ( J Am Heart Assoc. 2016;5:e002288 doi: 10.1161/JAHA.115.002288)
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B lood outgrowth endothelial cells (BOECs) represent aneasy accessible, culture-expandable cell source with
endothelial lineage specification. BOECs belong to the family
of endothelial progenitor cells (EPCs), which harbors a
heterogeneous selection of different cell types, participating
in and modulating neovascularization. Distinct EPC subtypes
are defined using different culture techniques and/or combi-
nations of cell surface markers.1–3 BOECs, also referred to as
circulating endothelial colony-forming cells (ECFCs) or late
outgrowth EPCs, are the only cell type featuring the
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characteristics of a “true” EPC, given that these cells are self-
renewing, clonogenic, and able to form capillary-like struc-
tures and integrate into functional blood vessels in vitro and
in vivo, respectively.4
Refractory angina is an increasingly prevalent clinical
syndrome with an estimated incidence between 5% and 10%
of patients undergoing cardiac catheterization.5 In patients
with ischemic heart disease, refractory to optimal medical
treatment and percutaneous or surgical revascularization,
progenitor cell transfer may constitute a promising biological
alternative (“biological bypass”).6 Autologous BOECs are able
to induce neovascularization not only by incorporation into
functional vessels, but also through paracrine modulation.7,8
One of the major concerns when envisioning autologous
(progenitor/stem) cell therapy in cardiovascular medicine, is
the presumed dysfunctional progenitor cell phenotype in older
and diseased patients burdened with risk factors, as evi-
denced for early outgrowth EPCs of monocytic origin (also
known as circulating angiogenic cells),9–12 CD133+/VEGFR2+
circulating EPCs,10,13 colony-forming-unit EPCs (CFU-Hill),13,14
bone-marrow–derived mononuclear cells (MNCs)15 and
hematopoietic stem cells.11
Because no data are currently available on BOEC out-
growth and functionality in patients with the greatest unmet
clinical need, we compared outgrowth efficiency and in vitro
and in vivo functional characteristics of BOECs from patients
with severe, but stable, ischemic cardiomyopathy (ICMP) and
BOECs from both healthy age-matched (ACON) and young
(CON) control subjects.
Methods
Study Design
BOECs were isolated from peripheral blood of patients with
stable ischemic cardiomyopathy (left ventricular ejection
fraction [LVEF] ≤45%; 18–80 years) (ICMP: n=45; Table 1)
in follow-up at the outpatient heart failure clinic of the
Department of Cardiovascular Diseases at University Hospi-
tals (Leuven, Belgium). The study protocol was approved by
the Medical Ethics Committee (S51940), and informed
consent was obtained from all patients. The control group
consisted of healthy individuals (18–80 years; Table 1) with
no evidence/history of coronary artery disease, divided in an
age-matched (ACON: n=32) and young (CON: n=55) control
populations.
BOEC Isolation and Expansion
BOECs were isolated and expanded as previously described,
with minor modifications.4,8 In short, the mononuclear
fraction from 40- to 60-mL venous blood samples was
isolated using Ficoll Paque Plus (GE Healthcare, Little
Chalfont, UK) density centrifugation. Cells were resuspended
in EBM2 supplemented with a bullet kit (Lonza, Basel,
Switzerland), excluding the provided gentamicin and amfo-
tericin singlequots. In addition, the medium was supple-
mented with an extra 13% of FBS, MEM-NEAA (Gibco, Grand
Island, NY), 1% penicillin/streptomycin (Gibco), and 1:550
b-Mercaptoethanol (Gibco). Cells were cultured on collagen
type I precoated dishes (Cellcoat; Greiner Bio-One GmbH,
Kremsm€unster, Austria) in a 21% O2, 5% CO2 incubator.
Table 1. Clinical Characteristics of Study Subjects
ICMP
(n=45)
CON
(n=55)
ACON
(n=32)
Age, y 661 341 601
M/F (%) 91/9 59/41 25/75
LVEF (%) 312 — —
LVEDD, mm 561 — —
Cardiovascular risk factors ND
Hypertension 29/45 7/32
Diabetes 17/45 0/32
Hyperlipidemia 38/45 7/32
Obesity 14/45 6/32
Smoking 38/45 10/32
Familial cardiovascular risk 23/45 —
Extent of coronary
artery disease
NA —
One-vessel disease 8/45
Two-vessel disease 12/45
Three-vessel disease 25/45
Medical treatment 0/55
Aspirin 26/45 0/32
Thienopyridin 11/45 0/32
Statin 42/45 2/32
Beta-blocker 42/45 0/32
ACE inhibitor/ARB 38/45 1/32
Spironolactone 23/45 0/32
Device treatment 0/55 0/32
CRT-P 3/45
CRT-D 8/45
ICD 7/45
Blood outgrowth endothelial cell (BOEC) isolations were performed in 45 patients with
ischemic cardiomyopathy (ICMP), 55 young healthy controls (CON), and 32 age-matched
controls (ACON). Left ventricular ejection fraction (LVEF) and left ventricular end-
diastolic diameter (LVEDD) were measured by transthoracic echocardiography. ACE
inhibitor indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; CRT-D, cardiac resynchronization therapy incorporating an implantable
cardioverter defibrillator; CRT-P, cardiac resynchronization therapy without implantable
cardioverter defibrillator; ICD, implantable cardioverter defibrillator; NA, not applicable;
ND, not determined.
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Individual BOEC colonies were picked at days 21 to 28 and
pooled for further polyclonal expansion up to passage 7 or
growth arrest. Phenotyping and functional evaluation was
performed at passage 3 to 5 (Figure 1). Mycoplasma
contamination was excluded, using the MycoAlert Myco-
plasma detection kit (Lonza), following the manufacturer’s
instructions.
Confirmation Endothelial Phenotype
Cells were stained with Ulex europeus agglutinin (UEA)-lectin
(Sigma-Aldrich). Dil-AcLDL uptake (Invitrogen, Carlsbad, CA)
and cell surface markers were quantified using flow cytometry
(BD FACS Canto II; BD Biosciences, San Jose, CA). CD309
(vascular endothelial growth factor receptor 2; VEGFR-2),
CD146 (melanoma cell adhesion molecule), and CD31
(platelet endothelial cell adhesion molecule 1) were selected
as endothelial markers, CD34 and CD133 as progenitor
markers, and CD45 as a panleukocyte exclusion marker.
Antibodies and isotype controls were from Miltenyi Biotec
(Cambridge, MA). Gene expression was studied using real-
time quantitative PCR (RT-qPCR; StepOnePlus; Applied
Biosystems, Foster City, CA) and TaqMan Gene Expression
Assays (Life Technologies, Carlsbad, CA), focusing on angio-
genic growth factors and endothelial markers (Table 2, top).
Results are expressed as a 2DCT-value, relative to HPRT as
the housekeeping gene. In addition, the angiogenic secretome
was studied in 24-hour conditioned medium (EBM2/2%FBS)
by ELISA (PLGF, angiopoietin-2 [ANG-2], fibroblast growth
factor [FGF] 2, platelet-derived growth factor-BB [PDGF-BB],
VEGF165, insulin-like growth factor 1 [IGF-1], and HGF,
hepatocyte growth factor [HGF]; Quantikine; all from R&D
Systems, Minneapolis, MN; Table 2, bottom).
Proliferation Potential
Cell numbers were calculated at every passage in order to
derive expansion curves and calculate population doubling
times throughout the entire expansion process. In addition to
growth kinetics, senescence was quantified by senescence-
associated b-galactosidase staining (Senescence Detection
Kit; BioVision, Inc., Milpitas, CA). The number of blue cells was
manually counted and reported as a percentage of the entire
cell population.
In Vitro Oxidative Stress
Production of reactive oxygen species (ROS) was quantified
using CM-H2DCFDA (Molecular Probes, Eugene, OR) as a
fluorescent ROS indicator (Ex/Em: 492-495/517-527). Cells
were loaded with a final dye concentration of 10 lmol/L for
30 minutes at 37°C. Intensity of the fluorescence was
Blood 
EBM2 / 15% FBS 
Collagen 
21% O2 
5% CO2 
37° C 
BOEC-CFU: Day 11 
Picking 
Colonies 
Day 21-28 
Day 10-16 
Day 0 
Expansion  
(Passage 5-7) 
1.5-2 Months 
Phenotyping 
(Passage 3-5) 
Figure 1. BOEC isolation and expansion process. Mononuclear cells (MNCs) were isolated from a single
40- to 60-mL venous blood sample by Ficoll density centrifugation. MNCs were seeded on collagen type I
precoated dishes and cultured in a 21% O2, 5% CO2 incubator using EBM2 medium. Medium was changed
daily during the first week and every other day after. BOEC colonies started to appear at days 10 to 16
(scale bar, 200 lm). Individual BOEC colonies were picked at days 21 to 28, pooled, and culture expanded
up to passage 7 or growth arrest. Phenotypic analysis was performed between passages 3 and 5. BOEC
indicates blood outgrowth endothelial cell; CFU, colony-forming units.
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measured using a fluorescence plate reader at baseline, 10 and
45 minutes after exposure to 500 lmol/L H2O2. Additionally,
cells were exposed to 1000 lmol/L of H2O2 for 24 hours, after
which cell viability was quantified by flow cytometry using 7-
aminoactinomycin D (7-AAD) as a viability marker.
In Vitro Neovascularization Potential
In a matrigel “network remodeling” (Tube Formation) assay
(BD Matrigel Basement Membrane Matrix, 354234; BD
Biosciences), a total of 75 000 BOECs were seeded per 24-
well, coated with 300 lL of Matrigel. Phase contrast mosaic
images were acquired of the complete well after 6 hours of
incubation. The cellular network was manually delineated in
order to semiautomatically quantify total network length and
the number of intersections using ImageJ software (National
Institutes of Health, Bethesda, MD). Additionally, sprouting
angiogenesis was studied using a three-dimensional (3D)
spheroid sprouting assay in collagen gel, as previously
described with minor modifications.16 In short, BOEC
spheroids containing 1000 cells were generated by suspen-
sion culture in EBM2 culture medium containing 0.25% (w/v)
carboxymethylcellulose, seeded in nonadherent round-bot-
tomed 96-well plates. Under these conditions, all suspended
cells contribute to the formation of a single BOEC spheroid
per well. These spheroids were harvested within 24 hours and
embedded in collagen gels (Rat Tail Collagen Type I; Corning,
Corning, NY), as previously described.16 The length of the 3
longest capillary-like sprouts that had grown out of each
spheroid was measured after 24 hours. A total of 202
spheroids per sample were analyzed.
In Vivo Neovascularization Potential
All animal procedures were approved by the Ethics Committee
on Animal Use of KU Leuven (Leuven, Belgium) and conform
to the Guide for the Care and Use of Laboratory Animals
published by the U.S. National Institutes of Health. Female 8-
to 10-week-old athymic NMRI nude mice (Janvier Labs, Le
Genest-Saint-Isle, France) were anesthetized with an intraperi-
toneal injection of ketamine (100 mg/kg) and xylazine
(15 mg/kg). The common, superficial, and deep femoral
artery of the right leg were ligated and transsected in
between. Laser Doppler measurements (PIM-II; Lisca Devel-
opment AB, Link€oping, Sweden) were performed under 2%
isoflurane gas anesthesia and temperature-controlled condi-
tions (37°C) 5 days after hindlimb ischemia surgery to assess
degree of flow reduction. Only animals with ≥55% flow
reduction in the ischemic versus nonligated control limb were
included in the study.
Table 2. Transcriptional Analysis and Secretome of BOECs
RT-qPCR (2DCT vs HPRT) ICMP (n=15) CON (n=9) ACON (n=10) 1-Way ANOVA
Endothelial markers
vWF 7.1202.620 7.3304.370 3.3900.655 P=0.69
NOS-3 0.1010.029 0.0720.044 0.1840.045 P=0.05
Angiogenic/arteriogenic growth factors
PLGF 1.0100.319 0.6390.230 0.7550.216 P=0.97
ANG-2 1.1400.592 0.6420.216 1.470.381 P=0.06
FGF-2 0.3370.110 0.3440.082 0.2430.040 P=0.46
PDGF-BB 0.9180.362 0.6480.131 0.8090.309 P=0.65
VEGF 0.0630.017 0.0870.037 0.0830.015 P=0.20
IGF-1 0.0150.008 0.0060.002 0.0160.007 P=0.81
HGF 0.0070.004 0.0070.003 0.0310.008 P<0.05*,†
ELISA ICMP (n=15) CON (n=9) ACON (n=15) 1-Way ANOVA HCAEC Reference (n=3)
hPLGF (pg/106 cells) 57721525 61331475 2767368 P=0.13 2326579
hANG-2 (ng/106 cells) 14031 9618 8311 P=0.66 124
hFGF (pg/106 cells) 965730 439160 568 P<0.05*,† 13354
hPDGF-BB (pg/106 cells) 17050 18490 378 P=0.04 208
ANG-1, EGF, HGF, IGF1, and VEGF below detection limit of the assay. All transcriptional results are expressed as a 2DCT-value, relative to HPRT as the housekeeping gene. ACON indicates
age-matched controls; ANG-1/2, angiopoietin-1/2; BOEC(s), blood outgrowth endothelial cell(s); CON, healthy young controls; FGF, fibroblast growth factor; HCAEC, human coronary
artery endothelial cells; HGF, hepatocyte growth factor; ICMP, ischemic cardiomyopathy patients; IGF-1, insulin-like growth factor 1; NOS-3, nitric oxide synthase 3; PDGF-BB, platelet-
derived growth factor-BB; PLGF, placental growth factor; RT-qPCR, reverse-transcriptase polymerase chain reaction; VEGF, vascular endothelial growth factor; vWF, von Willebrand factor.
One-way ANOVA post-test comparison: *P<0.05: ICMP vs ACON; †CON vs ACON.
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Figure 2. BOEC outgrowth characteristics. BOECs can be isolated to the same extent
from patients and controls (A), irrespective of age (B), severity of the disease process (C,
D, and E), and cardiovascular risk factors (F and G). The linear regression line is
surrounded by 95% confidence bands (C). 1/2/3-VD indicates 1/2/3-vessel disease;
ACON, age-matched controls; CON, healthy young controls; CVRF, cardiovascular risk
factors; DM, diabetes mellitus; ICMP, ischemic cardiomyopathy patients; LVEDD, left
ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; y, years.
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Intramuscular injections of 250 000 BOECs from
patients (ICMP) or young controls (CON) versus vehicle
control (PBS) were performed in the ischemic hindlimb,
5 days after the ligation procedure. Cells were resuspended
in 100 lL of PBS and subsequently injected into the thigh
region (5910 lL) and gastrocnemius muscle (5910 lL)
using a 1-mL 29G syringe. Intraperitoneal anti-asialo-GM1
injections (Wako Chemicals, Inc., Dallas, TX) were per-
formed once a week to suppress residual natural killer cell
activity.
Mice were euthanized 21 days after femoral artery ligation.
At sacrifice, mice were sedated with an intraperitoneal
injection of Nembutal 70 mg/kg. A midline sternotomy was
performed to expose the heart, followed by insertion of a
winged 25G needle (Mycroflex; Vygon, Ecouen, France) into
the LV apex and removal of the right auriculum. Vessels were
perfused by the LV cavity with 20 mL of saline, containing
100 IU/mL of unfractionated heparin, in order to remove the
blood and prevent clotting. Tissue was subsequently fixed by a
15-mL perfusion with neutral buffered formalin 10%, followed
by 20 mL of saline to wash out the fixative. A final perfusion
with a preheated mixture of 30% barium sulphate (Micro-
paque; Guerbet, France) and 2% gelatin was performed in
order to visualize the vessel tree on post-mortem angio
CD34 CD133 CD309
CD45 CD146 CD31
Flow Cytometry ICMP (n=17)
(% Positive Cells)
CON (n=13)
(% Positive Cells)
P-Value
CD45 0.0±0.0 0.0±0.0 /
CD146 98.4±0.3 96.1±1.4 0.38
CD31 98.5±0.3 97.9±0.7 0.26
CD309 81.7±2.2 70.5±6.4 0.08
CD34 57.2±7.3 71.6±9.3 0.17
CD133 0.1±0.0 0.0±0.0 0.72
Phase Contrast: BOEC Colony
A
B
C
D
CD31 UEA-Lectin DAPI
Dil-AcLDL UEA-Lectin DAPI
Figure 3. BOEC phenotype. BOECs display the typical cobblestone morphology (A) (scale bar, 200 lm), stain positive for UEA-lectin and the
endothelial marker, CD31 (B) (scale bar, 20 lm), and take up acetylated LDL (C) (scale bar, 20 lm). Representative flow cytometry analysis (D)
for endothelial markers (CD31+/CD309+/CD146+), progenitor markers (CD34+/CD133), and a panleukocytic marker (CD45) on ICMP-
BOECs. Flow cytometry data (red line in histogram) are expressed in relation to respective isotype controls (black line in histogram) and a
quantitative comparison with CON-BOECs is shown in the table. BOEC indicates blood outgrowth endothelial cell; CON, healthy young controls;
DAPI, 4’,6-diamidino-2-phenylindole; ICMP, ischemic cardiomyopathy patients; LDL, low-density lipoprotein; UAE, Ulex europeus agglutinin.
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microCT (computed tomography). Mice were stored on ice
overnight to solidify the gelatin and fix the contrast agent in
the vessels.
The hind limbs were scanned with a high-resolution
microCT (50 kV, 200 lA, 10 W; SkyScan-1172; SkyScan,
Virginia Beach, VA) at a pixel size of 8 lm, providing highly
detailed, quantitative 3D structural data of the perfused
“vessel tree” of the complete limb. The individual two-
dimensional (2D) images were reconstructed into a 3D data
set with isotropic voxel size of 8 lm using the manufacturer’s
dedicated software (NRecon; SkyScan). Analysis was per-
formed using in-house developed custom-made software
(MeVisLab based; MeVis Medical Solutions AG, Bremen,
Germany) after an additional downsampling step by a factor of
4, for reasons of computational feasibility. The 3D vessel tree
was automatically segmented for semiautomatic quantifica-
tion. Data in the ligated leg were analyzed versus the
nonligated control leg.
Histology: Arthrobacter luteus Repeats and
Combined hCD31/BS-I Lectin Staining
Adductor and gastrocnemius muscles, as well as lung, spleen,
liver, kidney and heart on a separate set of animals not
perfused with gelatin/barium-sulfate were collected and
paraffin-embedded to study BOEC incorporation and biodis-
tribution. BOEC-incorporation into the vasculature of adductor
and gastrocnemius muscles, was studied by combined
chromogenic in situ hybridization for Arthrobacter luteus
(ALU)-repeats (ALU Positive Control Probe-II and ISHiVIEW
Blue Plus Detection Kit; Ventana Medical Systems, Inc., Oro
Valley, AZ), as the primate-specific sequence, and dual
immunofluorescence staining for human (h) CD31 (anti-
hCD31 IgG1,j, m0823; Dako, Carpinteria, CA) and BS-I Lectin
(L3759; Sigma-Aldrich) on adjacent sections. An initial acute
retention and biodistribution study was performed, 24 hours
after intramuscular injections (6 days after ligation) of
Figure 4. BOEC expansion potential. Growth kinetics, studied by population doubling times (A3) and the slope of the log10(expansion curves)
(A1,2), showed similar proliferation rates in BOECs from ICMP patients and controls. Growth kinetics were studied from the start of the
polyclonal phase, defined as day 0, the time point at which individual BOEC colonies were picked and pooled for culture expansion. The number
of senescent cells, quantified as the percentage of blue cells in the senescence-associated b-galactosidase staining (B1) (scale bar, 200 lm),
did not differ between patients and controls (B2). ACON indicates age-matched controls; BOEC, blood outgrowth endothelial cell; CON, healthy
young controls; ICMP, ischemic cardiomyopathy patients.
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250 000 BOECs labeled by lentiviral overexpression of Cherry
fluorescent protein. Moreover, chronic engraftment was
quantified at 21 days.
Statistical Analysis
All data are presented as meanSEM. Intergroup differences
were analyzed using 2-tailed unpaired t tests or 1-way ANOVA
followed by a Bonferroni post-hoc test for normally distributed
data. Non-normally distributed data were compared using
a nonparametric Mann–Whitney test or nonparametric
Kruskal–Wallis test followed by Dunn’s post-hoc test. Pearson
correlations were performed to analyze linear covariation
between normally distributed data sets, whereas Spearman
nonparametric correlation was performed for nonparametric
datasets. A probability value of P<0.05 was considered
statistically significant. All analyses were performed using
Prism 5.0a software (version 5.0a; GraphPad Software Inc., La
Jolla, CA).
Results
Patient Characteristics
BOEC isolations were performed in 45 patients (ICMP,
661 years) and 32 healthy age-matched (ACON,
601 years) and 55 healthy young (CON, 341 years)
controls (Table 1). Global systolic LV function was impaired
(LVEF 312%) without concomitant adverse LV remodeling
(left ventricular end diastolic diameter [LVEDD], 561 mm) in
the majority of patients. Adverse LV remodeling, defined as an
LVEDD ≥60 mm on a transthoracic acquired echocardiogra-
phy parasternal long axis view, was present in 12 of 45
(26.7%) patients. Four patients were excluded from the study
because blood was taken less than 1 month after device
implantation.
BOEC Outgrowth Efficiency
Starting from 40 to 60 mL of whole blood, a mean of 3.60.6
BOEC colonies/1009106 MNCs could be obtained from
patients versus 3.50.9 from age-matched controls and
2.60.4 from healthy young controls (P=0.29; Figure 2A).
Colonies could be obtained in 84% of ICMP, 72% of ACON and
82% of CON. The number of BOEC colonies obtained in our
ICMP population increased with age (r=0.42; P<0.01; Fig-
ure 2B), but was not affected by severity of the disease
process, assessed by LVEF (r=0.12; Figure 2C) or adverse
LV remodeling (Figure 2D). BOEC outgrowth was independent
of the extent of coronary artery disease, number of cardio-
vascular risk factors, and presence of diabetes mellitus
(Figure 2E through 2G).
BOEC Phenotype
BOECs uniformly expressed CD31, bound lectin, and took up
Dil-AcLDL (representative examples are shown in Figure 3A
through 3C). Flow cytometry evaluation of endothelial (CD31+,
CD309+, and CD146+) and progenitor (CD34+, CD133) cell
surface markers did not differ between groups (Figure 3D).
The panleukocyte marker, CD45, was absent in all groups. RT-
qPCR neither showed differences in expression for additional
endothelial markers, such as VWF and NOS3 (Table 2, top).
Figure 5. BOEC response to oxidative stress: ROS production
was quantified using CM-H2DCFDA as a fluorescent ROS indicator.
No differences were noted in baseline ROS production in BOECs
isolated from ICMP and CON (A). Moreover, induction by
500 lmol/L of H2O2 showed a similar increase in ROS production
in ICMP and CON (A). Additionally, 24 hours of exposure to
1000 lmol/L of H2O2 did not show significant differences in BOEC
viability between ICMP and CON, quantified by flow cytometry
using 7-AAD as a viability marker (B). 2-way RM ANOVA indicates 2-
way repeated-measures ANOVA; 7-AAD, 7-aminoactinomycin D;
BOEC, blood outgrowth endothelial cell; CON, healthy young
controls; ICMP, ischemic cardiomyopathy patients; ROS, reactive
oxygen species.
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BOEC Proliferation Potential
We aimed to expand our cells to a target dose of 309106
BOECs from 60 mL of whole blood, a cell number with proven
functional benefit in our porcine myocardial ischemia/reper-
fusion model.7 Proliferation potential, studied by growth
kinetics and senescence-associated b-galactosidase staining,
did not show differences between BOECs from ICMP and (A)
CON. Population doubling times (P=0.16) and slopes of the
log10(expansion curves) (P=0.38) showed comparable growth
kinetics (Figure 4A). The number of senescent cells was
5.82.1% in ICMP (n=17) versus 3.91.1% and 9.02.8% of
total BOECs in ACON (n=7) and CON (n=13), respectively
(P=0.19; Figure 4B). Starting from a single 60-mL blood
sample in our patient population, expansion up to 309106
BOECs was achieved in 52% of isolations, if initial BOEC
colonies were obtained. The number of initial BOEC colonies
(P<0.0001) and the time of appearance of the first clone
(P=0.005) were major predictors of expansion success. If
expansion up to 309106 cells could be achieved, the average
number of BOEC colonies to start from was 9.92.3/isolation
with an appearance at day 121. In contrast, if expansion up
to 309106 cells failed, on average only 2.50.5 colonies/
isolation were initially obtained with an appearance at day
161. Clinical, biochemical, or hematological predictors of
expansion potential could not be identified.
BOEC Response to Oxidative Stress
No differences were noted in baseline reactive oxygen species
(ROS) production in BOECs isolated from ICMP (n=5) and CON
(n=6; P=0.37; Figure 5A). Moreover, induction by 500 lmol/L
of H2O2 showed comparable increase in ROS production in
ICMP and CON, 10 and 45 minutes after exposure (P=0.60;
Figure 6. BOEC Matrigel network formation potential. Network remodeling was photographed using phase-contrast mosaic acquisition (A, top
panel) and subsequently manually delineated (A, lower panel—network delineation in red) in order to quantify total network length and the
number of intersections (scale bar, 1000 lm). Total network length (B1) and the number of intersections (B2) in patients did not differ from
controls. Severity of the disease process, assessed by left ventricular ejection fraction (LVEF), did not compromise in vitro network formation
potential (C1,2). Linear regression lines are surrounded by 95% confidence bands (C1,2). ACON indicates age-matched controls; BOEC, blood
outgrowth endothelial cell; CON, healthy young controls; ICMP, ischemic cardiomyopathy patients.
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Figure 5A). Additionally, 24 hours of exposure to 1000 lmol/
L of H2O2 did not show significant differences in BOEC viability
between ICMP (n=6) and CON (n=6; P=0.11; Figure 5B).
BOEC In Vitro Neovascularization Potential
We subsequently focused on functional neovascularization
potential of the obtained cell populations. In vitro vasculo-
genic potential, explored using the Matrigel network remod-
eling assay (Figure 6A), did not show differences in the
number of network intersections between cells from ICMP
and (A)CON (P=0.32; Figure 6B). Total network length did not
differ between cells from ICMP and (A)CON. An increase in
network length was, however, noted in aged versus young
controls. Severity of the disease process, assessed by LVEF,
did not impair in vitro network formation potential. On the
contrary, LVEF inversely correlated with total network length
(r=0.57; P=0.01; n=16) and the number of intersections
(r=0.53; P=0.03; n=16; Figure 6C). Body mass index (BMI)
was positively correlated with in vitro vasculogenic potential
(r=0.58; P=0.02; n=16). No other major clinical, biochemical,
or hematological predictors could be identified. Additionally,
in vitro angiogenesis potential, explored using a 3D spheroid
sprouting assay in collagen gel, did not show differences in
sprouting angiogenesis between BOECs from ICMP and CON
(P=0.70; Figure 7).
RTqPCR and ELISA documented a marked proangiogenic
profile with high expression of angiogenic growth factors
(ANG-2, PLGF, PDGF-BB, FGF-2, and VEGF) both in BOECs
from patients and controls (Table 2). ANG-2 and PLGF were
the most abundant angiogenic growth factors in 24-hour
conditioned medium, with similar amounts secreted by BOECs
from ICMP and healthy subjects ([A]CON) (P=0.66 and 0.13
for ANG-2 and PLGF, respectively).
BOEC In Vivo Neovascularization Potential
Initial acute retention and biodistribution studies, using
Cherry-labeled BOECs, documented multiple clusters and
singlets of transplanted cells in the femoral and tibiofibular
region 24 hours after intramuscular cell delivery (average of
312 BOECs/4.5 mm2), mainly localized in perimuscular
connective tissue (Figure 8). No detectable distribution was
observed in lungs, spleen, liver, kidneys, and heart.
Doppler flow index at inclusion (5 days after hindlimb
ischemia surgery) was similar in all groups (vehicle control:
35.91.5; CON-BOECs: 35.51.8; ICMP-BOECs: 35.92.0;
P=0.98). High-resolution angio microCT of the upper leg
confirmed enhanced BOEC-mediated arteriogenesis in com-
parison to vehicle control, 21 days after surgery (Figure 9).
Although total vessel length and the number of vessel
branch points tended to be increased after BOEC delivery
from both CON and ICMP (Figure 9B), therapeutic effects
were confined to smaller arterioles with a diameter ranging
from 32 to 64 lm (Figure 9D), corresponding to collateral
arteries, as documented by Scholz and Schaper.17,18
Importantly, increased arteriogenesis was observed after
transplantation of BOECs from healthy young controls
(P=0.048) and ICMP patients (P=0.025) over vehicle
control, both to a similar extent (P=0.831). Clinically,
BOECs were able to prevent additional amputations after
cell delivery (5 days after hindlimb ischemia surgery). A
total of 3 of 14 animals suffered from additional amputa-
tions after injections of vehicle control versus none in the
BOEC-injected groups.
Immunostaining for human CD31 and in situ hybridiza-
tion for primate specific ALU-repeat sequences could detect
incorporation of rare human BOECs into murine vessels in
the ischemic hindlimb 21 days after surgery (Figure 10).
Engraftment, studied in 3 versus 3 mice, showed 42
A
B C
Figure 7. BOEC 3D spheroid sprouting assay: BOEC spheroids,
containing 1000 cells, were embedded into collagen gels. The
length of the 3 longest capillary-like sprouts that had grown out of
each spheroid was measured after 24 hours. No differences were
noted in average sprout length between ICMP and CON (A).
Representative images of sprouting BOEC spheroids from ICMP (B)
and CON (C) (scale bar, 200 lm). 3D indicates three-dimensional;
BOEC, blood outgrowth endothelial cell; CON indicates healthy
young controls; ICMP, ischemic cardiomyopathy patients.
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incorporated ICMP-BOECs/4.5 mm2 versus 32 incorpo-
rated CON-BOECs/4.5 mm2. This limited incorporation
after injection of 250 000 BOECs/mouse suggests a
concomitant paracrine contribution of the transplanted
cell population to their documented neovascularization
potential.7,8
Discussion
We report that BOECs can be successfully isolated and
culture-expanded from patients with severe, but stable,
ischemic cardiomyopathy, irrespective of age, severity of
myocardial systolic dysfunction, or degree of maladaptive LV
remodeling. These cells show a robust and consistent
endothelial progenitor phenotype with comparable prolifera-
tion kinetics and without evidence of increased senescence
when compared to cells isolated from young or age-matched
healthy subjects. We did not document differences in in vitro
neovascularization potential of BOECs from patients or
controls, because they form comparable vascular networks
in Matrigel, demonstrate similar sprouting potential in a 3D
spheroid-sprouting angiogenesis assay, and secrete high
Cherry Labeled BOECs
TOPRO3
BS1-Lectin              human-CD31              DAPI
A1 A2
B1 B2
Cherry Labeled BOECs
TOPRO3
ALU-Repeats
Figure 8. Acute BOEC retention. Confocal microscopy documents multiple clusters (A1) and singlets (A2) of Cherry-labeled BOECs (red),
24 hours after intramuscular injection into the ischemic hindlimb. These findings were confirmed by immunofluorescence microscopy for human
CD31 (red; labeling only transplanted cells) and BS-I-Lectin (green; labeling host endothelium) (B1) and in situ hybridization for primate-specific
ALU-repeat sequences (dark blue) on the respective adjacent slides (B2) (scale bar, 100 lm). Clusters and singlets of human BOECs are
indicated by white arrows. ALU indicates Arthrobacter luteus; BOEC(s), blood outgrowth endothelial cell(s); CON indicates healthy young
controls; ICMP, ischemic cardiomyopathy patients.
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levels of potent angiogenic and arteriogenic factors. After
in vivo cell transfer, BOECs from patients and healthy donors
increase collateral vascular remodeling in the thigh region of
nude mice, with significant induction of arterioles 32 to
64 lm in diameter and prevention of imminent amputations
after cell delivery.
In contrast to various other EPC subtypes studied as
biomarkers of cardiovascular risk and disease,14,19 we did not
observe inverse correlations between the number of BOEC
outgrowth colonies and severity of the ischemic atheroscle-
rotic disease process. We did not observe a disease-related
increase in the number of BOEC colonies obtained, as was
previously shown during active inflammation, tissue damage,
and intense vascular remodeling (acute myocardial infarc-
tion,20 acute ischemic stroke,21,22 rheumatoid arthritis,23
neovascular age-related macular degeneration,24 or extensive
burns25). In our patient population with stable ischemic heart
failure, optimally treated according to current guidelines, a
similar number of BOEC colonies were obtained in patients
and healthy controls. These findings are consistent with
earlier data in statin-treated patients with premature coronary
artery disease.26 Within our patient cohort, we did, however,
note a mild positive correlation between age and BOEC
outgrowth, absent in our control population.
Because of limited cell retention after intracoronary or
intramyocardial delivery, a sufficient cell mass is needed to
obtain therapeutic effects in the target region as previously
shown in domestic swine.7 Starting from a single 60-mL blood
sample, we were able to achieve our expansion goal of
309106 cells in 52% of patients, with similar growth kinetics
in controls. Given that we showed expansion success to be
highly dependent on the number of initial BOEC colonies
Figure 9. In vivo neovascularization potential assessed by angio microCT: Representative 3D reconstructions (left panel) and quantitative
analysis (right panel). Representative 3D angio microCT reconstructions illustrate an enhanced neovascularization response in the thigh region
after intramuscular injections of BOECs from both patients (ICMP) and CON (A). Twenty-one days after hindlimb ischemia surgery, angio microCT
quantifications documented a trend toward increased vessel length (B1) and number of vessel branch points (B2) in the thigh region (A and C)
after intramuscular BOEC injections of patients (ICMP) and CON in comparison to vehicle control (PBS). BOEC-mediated effects were confined to
arterioles 32 to 64 lm in diameter (2-tailed unpaired t tests) (D). All results from the ischemic hindlimb (HLI) are expressed in relation to the
contralateral control leg (CONT). 3D indicates three-dimensional; BOEC, blood outgrowth endothelial cell; CON indicates healthy young controls;
CT, computed tomography; ICMP, ischemic cardiomyopathy patients; ROI, region of interest.
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obtained, increasing the number of MNCs by increasing the
volume of the blood sample or using leukapheresis could
further enhance expansion success.
In contrast to various other cell types, we observed
preserved neovascularization potential of BOECs derived from
an older patient population with severe ICMP. Ingram et al.
reported that BOECs contain a complete hierarchy of low- and
high-proliferation potential cells, analogous to the hematopoi-
etic cell system.27 Moreover, long-term culture conditions
may erase the functional “fingerprint” of various microenvi-
ronmental factors, present in the donor milieu. Cell types with
a previously documented dysfunctional phenotype in an older
patient population with ischemic heart disease were only
exposed to short-term in vitro cell culture (eg, circulating
angiogenic cells and colony-forming-unit EPCs) or no in vitro
environment at all (eg, CD133+/VEGFR2+ circulating EPCs
and bone-marrow–derived MNCs). Hence, “weaning off”
donor microenvironmental influences and positive selection
based on proliferation potential were only minimally or not
present. Specific reports on BOEC functionality and prolifer-
ation potential in various other disease states are, however,
not uniform. Functional impairment has been reported, related
to age,28 type 2 diabetes,29 obesity,30 pulmonary arterial
hypertension,31 and smoking/chronic obstructive pulmonary
disease.32 On the other hand, previous reports in treated
coronary artery disease26,33,34 and arterial hypertension35
documented similar BOEC functionality in comparison
to healthy controls. Moreover, improved BOEC functional-
ity has been demonstrated in neovascular age-related
macular degeneration,24 ischemic stroke,22 and extensive
burns.25,26,33–35 In comparison to healthy controls, our
findings did not demonstrate differences in BOEC functionality
hCD31  BS1-Lecn 
DAPI 
B1 B2 
B3 B4 
hCD31 BS1-Lecn 
DAP
I 
A1 A2 
A3 A4 
B5 A5 
Figure 10. Human BOECs incorporate into murine blood vessels. Immunofluorescence costaining for human CD31 (A1,B1), BS-I-Lectin (A2,
B2), and DAPI nuclear counterstain (A3,B3) demonstrates human BOEC incorporation (red) into murine blood vessels (green) in the adductor (A)
and gastrocnemius (B) region, 21 days after hindlimb ischemia surgery (scale bar, 20 lm). These findings were confirmed by in situ
hybridization for primate-specific ALU-repeat sequences on adjacent slides, showing incorporated human BOECs in dark blue (A5,B5) (A5 scale
bar, 100 lm; B5 scale bar, 50 lm). Field of view of the immunofluorescence images is indicated in red. Engrafted human BOECs are indicated
by white arrows. ALU indicates Arthrobacter luteus; BOEC(s), blood outgrowth endothelial cell(s); DAPI, 4’,6-diamidino-2-phenylindole.
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and proliferation potential in a patient population with severe,
but stable, ischemic heart failure. We noted, however, mild
positive correlations between Matrigel network formation
potential and both degree of systolic LV dysfunction and BMI
within our patient cohort. No differences were noted in
response to oxidative stress, studied by ROS induction and
cell viability.
We studied in vivo cell-mediated neovascularization poten-
tial using high-resolution angio microCT because of its ability
to quantitatively assess the complete “vessel tree” in 3D.
Histology is mainly restricted to evaluating vascular density in
a limited 2D area of view, whereas laser Doppler flowmetry is
only reporting superficial blood flow (200–300 lm penetra-
tion depth), classically in the foot region.36 Collateral vascular
remodeling (arteriogenesis) has been postulated as the most
important mechanism to compensate for bulk perfusion loss.
Efficient collateral formation is a critical determinant of tissue
vulnerability and preservation during ischemia. Occlusion of
the femoral artery in a hindlimb ischemia model results in
development of collateral vessels in the upper leg, relatively
close to the site of occlusion. In contrast, ischemia and
angiogenesis occur in the lower leg and foot.37 We conse-
quently focused on the thigh region as the readout for
collateral vascular remodeling, and observed that cells from
both patients and controls support the arteriogenesis process
to a similar extent, especially at the level of arterioles (32–
64 lm in diameter). Extensive (ultra)structural histological
analysis by Scholz and Schaper in murine hindlimbs previously
identified collateral arteries in the 40- to 70-lm diameter
range.17,18 We documented a significant BOEC-mediated
increase in vascular length within this specific size range.
A trend toward a BOEC-mediated increase of vessel length
and number of branch points of the complete vessel tree in
the thigh region of the ligated leg was noted. These results
did, however, not reach statistical significance, given that the
therapeutic effects were confined to one specific size range
(arterioles 32–64 lm in diameter). Arteriogenesis relies on a
complex interplay of many growth factors, of which ANG-2,
PLGF, FGF, and PDGF-BB were all demonstrated to be
secreted by BOECs.37–40
Acute retention studies documented BOECs, mainly
clustered within the perimuscular compartment 24 hours
after intramuscular injection. At 21 days, we noted disap-
pearance of the BOEC clusters in the perimuscular com-
partment and appearance of isolated BOECs in the vascular
compartment. We observed only limited incorporation/
engraftment of BOECs into functional blood vessels after
intramuscular delivery of 250 000 cells per mouse, suggest-
ing a concomitant paracrine contribution of the transplanted
cell population to their neovascularization potential. These
findings indicate migration toward and engraftment within
the vascular compartment to perform their biological effects,
“sustained” release of a proangiogenic/-arteriogenic growth
factor “cocktail” with or without incorporation into functional
vessels. ANG-2 and PLGF were found to be the most
abundantly secreted angiogenic growth factors, independent
of underlying ischemic disease. Both ANG-2 and PLGF play
an important role in the complex cytokine cocktail, mediat-
ing the overall neovascularization process in ischemic
disease.37–47
In conclusion, we report that BOECs can be isolated and
culture-expanded from patients with severe, but stable, ICMP
and offer an easily accessible, clonally expandable cell source
with profound neovascularization potential. In contrast to
impaired functionality of other progenitor cell types derived
from patients with advanced cardiovascular disease, BOECs
retain a robust proangiogenic profile in vitro and in vivo and
hold promise for autologous cell therapy in severe or
refractory ischemic heart disease.
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